IP Verse

Calcimimetics And Methods For Their Use - EP2776129

The patent EP2776129 was granted to KAI Pharmaceuticals on Jun 17, 2020. The application was originally filed on Nov 12, 2012 under application number EP12791926A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2776129

KAI PHARMACEUTICALS
Application Number
EP12791926A
Filing Date
Nov 12, 2012
Status
Patent Maintained As Amended
May 15, 2020
Grant Date
Jun 17, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXAL SANDOZDec 22, 2017TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2009023652
DESCRIPTIONUS2011028394
DESCRIPTIONUS5246925
DESCRIPTIONUS5304121
DESCRIPTIONUS5587497
DESCRIPTIONUS5602116
DESCRIPTIONUS5861386
DESCRIPTIONUS5869473
DESCRIPTIONUS5886026
DESCRIPTIONUS6011068
DESCRIPTIONUS6031003
DESCRIPTIONUS6051567
DESCRIPTIONUS6099562
DESCRIPTIONUS6265392
DESCRIPTIONUS6274169
DESCRIPTIONUS6903083
INTERNATIONAL-SEARCH-REPORTUS2011028394
OPPOSITIONWO2011014707

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ARORA ET AL., INT. J. PHARMACEUTICS, (2008), vol. 364, page 227-
DESCRIPTION- "Gene Expression Technology", Methods in Enzymology, ACADEMIC PRESS, (1991), vol. 185-
DESCRIPTION- Gene Transfer and Expression Protocols, THE HUMANA PRESS INC., pages 109 - 128-
DESCRIPTION- MEIDAN ET AL., AMERICAN J. THERAPEUTICS, (2004), vol. 11, page 312-
DESCRIPTION- NANDA ET AL., CURRENT DRUG DELIVERY, (2006), vol. 3, page 233-
DESCRIPTION- PRAUSNITZ; LANGER, NAT. BIOTECHNOLOGY, (2008), vol. 11, pages 1261 - 68-
EXAMINATION- BRIESE SONIA ET AL, "Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy.", NEPHROLOGY, DIALYSIS, TRANSPLANTATION : OFFICIAL PUBLICATION OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION - EUROPEAN RENAL ASSOCIATION JUL 2006, (200607), vol. 21, no. 7, ISSN 0931-0509, pages 1906 - 1914-
EXAMINATION- NOONAN WILLIAM ET AL, "Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats", NEPHROLOGY DIALYSIS TRANSPLANTATION, (200812), vol. 23, no. 12, ISSN 0931-0509, pages 3824 - 3830-
INTERNATIONAL-SEARCH-REPORT- MUHAMMAD ZIAD SOUQIYYEH, FAISSAL ABDULRAHEEM SHAHEEN, "Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)", SAUDI JOURNAL FOR KIDNEY DISEASES AND TRANSPLANTATION, (2010), vol. 21, no. 1, pages 93 - 101, XP002692461 [I] 1-9 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- KATHERINE WESSELING-PERRY ET AL, "Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children", PEDIATRIC NEPHROLOGY, (20130201), doi:10.1007/s00467-012-2381-8, ISSN 0931-041X, XP055053936 [T] * the whole document *
INTERNATIONAL-SEARCH-REPORT- SVÁRA F., "Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach.", J REN CARE, (200903), vol. 35, no. 1, pages 3 - 6, XP002692460 [A] 1-9 * abstract * * page 2, column 1, paragraph 3 *
OPPOSITION- Baruch et al -Abstract-
OPPOSITION- "Chapter 1 Definition and classification of renal osteodystrophy and chronic kidney disease-mineral bone disorder (CKD-MBD)", Olgaard et al., The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease second edition, Oxford University Press, (20100101), pages 1 - 14, XP055447356-
OPPOSITION- Crommelin et al., "Delivery of pharmaceutical proteins", Crommelin et al., Michael E Aulton, Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, (20070000), pages 616 - 617, XP055448264-
OPPOSITION- Cunningham et al., "Chapter 27 Medical therapy in chronic kidney disease", Cunningham et al., Olgaard et al., The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease second, (20100101), pages 463 - 483, XP055448148-
OPPOSITION- "Design of dosage forms", Michael E Aulton, Aulton's Pharmaceutics Third Edition, Elsevier, page 8, XP055448261-
OPPOSITION- Edward F Nemeth, "Chapter 26. Calcimimetics and calcilytics in the treatment of chronic kidney disease-mineral and bone disorder", Edward F Nemeth, Olgaard et al., The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease second edition, (20100101), pages 443 - 461, XP055447380-
OPPOSITION- "FR-P01222", J Am Soc Nephrol, (20110000), vol. 22-
OPPOSITION- "LB-P03147", J Am Soc Nephrol, (20110000), vol. 22-
OPPOSITION- Poster by Baruch et al. presented at the ENDO2011 in Boston on June 5, 2011-
OPPOSITION- Poster P01222 submitted by the patentee in the US-
OPPOSITION- "Press release regarding a poster presentation of KAI-4169 Phase 2 clinical results at the American Soc. of Nephrology's Kidney Week 2011", URL: https://www.businesswire.com/news/home/20111111005115/en/KAI-Pharmaceuticals-Announces-Late-Breaker-Poster-Presentation-
OPPOSITION- "Press release regarding promising results of KAI-4169 for the treatment of CKD-MBD ", (20110700), URL: https://www.businesswire.com/news/home/20110607006164/en/KAI-Pharmaceuticals-Announces-Promising-Results-KAI-4169-Program-
OPPOSITION- Pschyrembel® Klinisches Wörterbuch, (20040000), vol. 260, page 1879-
OPPOSITION- "SAO014", Nephrology Dialysis Transplantation , (20120500), vol. 27, no. Supp 2, doi:10.1093/ndt/gfs193-
OPPOSITION- Shafi, "Chronic Kidney disease: Definition, epidemiology, cost, and outcomes", Chronic Kidney Disease, Dialysis, and Transplantation Third Edition, (20100000), pages 3 - 21 , 92-93 101-114, XP055448162-
OPPOSITION- Takehisa Kawata, Nobuo Nagano, Masaki Obi, Sonoe Miyata, Chika Koyama, Nami Kobayashi, Sachiko Wakita, Michihito Wada, "Cinacalcet suppresses calcification of the aorta and heart in uremic rats", Kidney international, Nature Publishing Group, New York, New York, (20081102), vol. 74, no. 10, doi:10.1038/ki.2008.407, ISSN 1523-1755, pages 1270 - 1277, XP055448187
OPPOSITION- T. KAWATA et al., "Cinacalcet suppresses calcification of the aorta and heart in uremic rats", Kidney International, (20081102), vol. 74, no. 10, pages 1270 - 1277, XP055448187
OPPOSITION- N. KOLEGANOVA et al., "A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia", Kidney International, (20090101), vol. 75, pages 60 - 71, XP055448180
OPPOSITION- P. RAGGI et al., "The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis", Nephrol. Dial. Transplant, (20110000), vol. 26, pages 1327 - 1339, XP055448200
OPPOSITION- P. Raggi, et al, "The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis", NEPHROLOGY DIALYSIS TRANSPLANTATION., OXFORD UNIVERSITY PRESS., GB, GB, (20110401), vol. 26, no. 4, doi:10.1093/ndt/gfq725, ISSN 0931-0509, pages 1327 - 1339, XP055448200
OPPOSITION- Klaus Olgaard, Ewa Lewin And Justin Silver, "Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD", NEPHROLOGY DIALYSIS TRANSPLANTATION., OXFORD UNIVERSITY PRESS., GB, GB, (20110401), vol. 26, no. 4, doi:10.1093/ndt/gfq862, ISSN 0931-0509, pages 1117 - 1119, XP055448194
OPPOSITION- K. OLGAARD et al., "Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD", Nephrol. Dial. Transplant, (20110401), vol. 26, no. 4, pages 1117 - 1119, XP055448194
OPPOSITION- S. WALTER et al., "Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients", J Pharmacol Exp. Ther, (20130801), vol. 346, no. 2, pages 229 - 240, XP055275398
OPPOSITION- M. J. ALADREN REGIDOR, "Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients", Clinical Nephrology, (20090200), vol. 71, no. 2, pages 207 - 213, XP055448208
OPPOSITION- M J Aladren Regidor, "Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients", CLINICAL NEPHROLOGY, DUSTRI VERLAG, NUENCHEN-DEISENHOFEN, DE, DE, (20090201), vol. 71, no. 2, doi:10.5414/CNP71207, ISSN 0301-0430, pages 207 - 213, XP055448208

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents